English | 繁體

Search in the results

UM

Browse/Search Results:  1-2 of 2 Help

Selected(0)Clear Items/Page:    Sort:
Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1-Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis Journal article
Wu, Hao Xiang, Pan, Yi Qian, He, Ye, Wang, Zi Xian, Guan, Wen Long, Chen, Yan Xing, Yao, Yi Chen, Shao, Ning Yi, Xu, Rui Hua, Wang, Feng. Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1-Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis[J]. Journal of Clinical Oncology, 2023, 41(9), 1735-1746.
Authors:  Wu, Hao Xiang;  Pan, Yi Qian;  He, Ye;  Wang, Zi Xian;  Guan, Wen Long; et al.
Favorite | TC[WOS]:30 TC[Scopus]:32  IF:42.1/37.4 | Submit date：2023/04/03
Pembrolizumab  Placebo  Camrelizumab  Nivolumab  Survival  Efficacy  Therapy  Safety  Chemo  
Facial nerve injury immune-related adverse events associated with adjuvant pembrolizumab therapy: A case report Journal article
Dang, Yazheng, Wang, Mingwei, Li, Wei, Gao, Hongxiang, Huang, Shigao, Tao, Q. I.. Facial nerve injury immune-related adverse events associated with adjuvant pembrolizumab therapy: A case report[J]. World Academy of Sciences Journal, 2020, 2(6).
Authors:  Dang, Yazheng;  Wang, Mingwei;  Li, Wei;  Gao, Hongxiang;  Huang, Shigao; et al.
Favorite | TC[Scopus]:0 | Submit date：2021/12/06
Cancer  Facial Nerve Injury  Immune- Related Adverse Events  Immunotherapy  Neurotoxicity  Pembrolizumab